Market news, stock analysis and investing ideas

Cue Biopharma Falls 80% Through Four Halts a Day After Q3 Results

Cue Biopharma closed at $2.83 on Nov. 17, down 79.93% from Monday, after four volatility halts. The Q3 results were filed Monday evening, and pre-market trading showed only a small decline.

Health Care sector
Photo: Pexels

Cue Biopharma, Inc. (NASDAQ: CUE) closed at $2.83 on Tuesday, Nov. 17, down 79.93% from Monday's close of $14.10. The company filed its third-quarter results at 4:52 p.m. ET Monday, after the close, and its earnings release reported a $50.0 million net loss.

The sell-off came well after the results

The results had been public since Monday evening, and the stock fell only modestly in after-hours and pre-market trading. The steep drop came in regular trading, during four volatility pauses. It is not clear what set off the selling once the market opened.

Shares sat near $13.50 pre-market, then collapsed in regular trading

The stock slipped 2.13% in after-hours trading Monday to $13.80, its first trading after the filing. In pre-market trading Tuesday it last traded at $13.50, 4.26% below Monday's close, on only 1,632 shares.

The regular session opened 7.66% below Monday's close, and the session high was $13.52. Nasdaq then paused trading four times for volatility (automatic five-minute halts when a price moves too far, too fast): 9:43 to 9:48 a.m., 9:48 to 9:53 a.m., 9:53 to 9:58 a.m. and 9:59 to 10:04 a.m. ET. The stock closed at its low of the day.

About 3.80 million shares traded in the regular session, against a 10-day average of 177,544 shares a day. That equals about 62% of the 6.15 million shares in the float, the shares available to trade freely. In after-hours trading as of 4:54 p.m., the stock was at $2.87, up 1.41% from the 4 p.m. close, on 230,557 shares.

Cue was already falling before the report. It lost 6.22% on Nov. 12, 7.89% on Nov. 13 and 12.53% on Nov. 16, and it was down 12.31% over the four weeks to Monday's close. The high for that period was $22.49 on Oct. 29.

A bigger loss, but not an obvious trigger

The GAAP loss of $4.74 a share was worse than analysts had expected. Even so, the stock's pre-market decline was small, so the earnings numbers do not explain the timing of the plunge.

The float is small, and Tuesday's regular-session volume was about 24 times the 10-day average.

Expenses and cash in the third quarter

The company tied the larger loss to clinical start-up costs and to non-cash stock-based compensation (equity awards that count as an expense but use no cash). The awards were granted after what the company called its strategic transformation in the second quarter of 2026.

  • Net loss: $50.0 million, against $7.4 million in the third quarter of 2025.
  • Revenue: $0.1 million, against $2.1 million a year earlier, because less revenue was recognized under its BI collaboration and license agreement.
  • Research and development expenses: $17.0 million, against $4.8 million.
  • General and administrative expenses: $29.8 million, against $4.9 million, mainly non-cash stock-based compensation.
  • Cash and cash equivalents: $57.9 million as of Sept. 30.

On the pipeline, the company reported positive Phase 2 topline results for CUE-221 in chronic spontaneous urticaria, a hives condition, on the primary endpoint of complete hives resolution. In a prespecified subgroup of patients with high baseline IgE, 78% on the 4 mg/kg dose reached complete hive resolution at week 12, against 0% on placebo.

The FDA has cleared the company's investigational new drug application for a CUE-221 food allergy program. Dosing is underway in the first cohort of a Phase 1 trial of CUE-401, an autoimmune candidate.

The ImmunoScape license agreement was amended a second time, which brought the total payment obligation to $5.5 million. Of that, $3.0 million is due in the fourth quarter of 2026.

What to watch next

  • Any company statement on Tuesday's trading.
  • The $3.0 million ImmunoScape payment scheduled for the fourth quarter of 2026.
  • Progress in the first CUE-401 dosing cohort.
  • The start of the CUE-221 food allergy program.

Bottom line

Cue lost almost four-fifths of its value in one session, and Monday evening's results do not clearly account for it. The company reported a $50.0 million quarterly loss, $57.9 million in cash and progress in two clinical programs. The cause of the sell-off is unclear.


This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.

This article is for informational purposes only and is not investment advice.

Read the original report